PF-04929113
- CAS No.
- 908115-27-5
- Chemical Name:
- PF-04929113
- Synonyms
- CS-33;snx54227;SNX-5422;PF-04929113;PF-04929113, >=98%;PF04929113 SNX-54227;PF-04929113(SNX5422);snx5422 PF 04929113;PF-04929113 USP/EP/BP;PF-04929113 SNX-5422 PF04929113 SNX5422
- CBNumber:
- CB52561489
- Molecular Formula:
- C25H30F3N5O4
- Molecular Weight:
- 521.53
- MDL Number:
- MFCD20526334
- MOL File:
- 908115-27-5.mol
| Melting point | 298-299℃ |
|---|---|
| Boiling point | 646.5±55.0 °C(Predicted) |
| Density | 1.48 |
| storage temp. | Store at -20°C |
| solubility | ≥23.85 mg/mL in DMSO with gentle warming; insoluble in H2O; insoluble in EtOH |
| form | solid |
| pka | 15.07±0.50(Predicted) |
| color | White to off-white |
| NCI Dictionary of Cancer Terms | SNX-5422 |
| FDA UNII | BF52J69Q8T |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302 | |||||||||
| Precautionary statements | P280-P305+P351+P338 | |||||||||
| NFPA 704 |
|
PF-04929113 price More Price(19)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 18270 | PF-04929113 ≥98% | 908115-27-5 | 1mg | $55 | 2024-03-01 | Buy |
| Cayman Chemical | 18270 | PF-04929113 ≥98% | 908115-27-5 | 5mg | $248 | 2024-03-01 | Buy |
| Cayman Chemical | 18270 | PF-04929113 ≥98% | 908115-27-5 | 10mg | $440 | 2024-03-01 | Buy |
| Cayman Chemical | 18270 | PF-04929113 ≥98% | 908115-27-5 | 25mg | $963 | 2024-03-01 | Buy |
| Usbiological | 474158 | PF 04929113 | 908115-27-5 | 100mg | $1932 | 2021-12-16 | Buy |
PF-04929113 Chemical Properties,Uses,Production
Uses
PF 04929113 can be used in pharmacological activity and therapeutic use in therapeutic breast cancer drug target for multiclass comparative virtual screening to identify novel Hsp90 inhibitors. HSP90
Biological Activity
pf-04929113 is an inhibitor of hsp90 [1].pf-04929113 is a water soluble and orally bioavailable prodrug of pf-04928473. it is rapidly absorbed and converted into pf-04928473 after oral administration. in mice bearing bt-474 tumor xenografts, treatment of pf-04928473 causes the degradation of the her2 client protein. and no obvious toxicity is observed when the dose of pf-04928473 is up to 150mg/kg. treatment of 100mg/kg pf-04928473 results in complete tumor growth inhibition and in some mice partial tumor regressions. pf-04928473 also shows significant antitumor activity in mice with h1650 xenografts. in addition, as an inhibitor of hsp90, pf-04928473 is reported to inhibit p-erk and p-akt, decrease cd31+ cells and mvd as well as a have an effect on angiogenesis in vivo [1, 2].
Enzyme inhibitor
This potent and selective HSP90 inhibitor (FW = 521.54 g/mol; CAS 908115-27-5; Solubility: 100 mg/mL DMSO, <1mg/mL H2O), also knownas SNX-5422 and (1R,4R)-4-(2-carbamoyl-5-(6,6-dimethyl-4-oxo-3- (trifluoromethyl)-4,5,6,7-tetrahydroindazol-1-yl)phenylamino)cyclohexyl 2- aminoacetate, targets heat shock protein-90 (Kd = 41 nM) and also inhibits Her-2 degradation (IC50 = 37 nM). PF-04929113 also shows potent antiproliferative activity against a broad range of cancer cell types, e.g. MCF-7 (IC50 =16 nM), SW620 (IC50 =19 nM), K562 (IC50 =23 nM), SK-MEL-5 (IC50 =25 nM), and A375 (IC50 =51 nM). SNX2112 inhibits in vitro proliferation, inducing G2/M arrest, and enhanced cytotoxicity, chemosensitivity, and radiosensitivity between 25 and 250 nM, decreasing expression and/or phosphorylation of EGFR, c-MET, AKT, ERK-1 and -2, IκB kinase, and STAT3, corresponding downstream NFκB, AP-1, and STAT3 reporter genes, and target oncogenes and angiogenic cytokines.
target
Hsp90
References
[1] chandarlapaty s, sawai a, ye q, scott a, silinski m, huang k, fadden p, partdrige j, hall s, steed p, norton l, rosen n, solit db. snx2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against her kinase-dependent cancers. clin cancer res. 2008 jan 1;14(1):240-8.
[2] okawa y, hideshima t, steed p, vallet s, hall s, huang k, rice j, barabasz a, foley b, ikeda h, raje n, kiziltepe t, yasui h, enatsu s, anderson kc. snx-2112, a selective hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via akt and erk. blood. 2009 jan 22;113(4):846-55.
PF-04929113 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 32957 | 60 |
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 32165 | 58 |
| Career Henan Chemica Co | +86-0371-86658258 +8613203830695 | laboratory@coreychem.com | China | 30240 | 58 |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | 1026@dideu.com | China | 22883 | 58 |
| Shenzhen Shengda Pharma Limited | 755-85269922 +8613424394241 | sales@shengdapharm.com | CHINA | 310 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 | sales@sarms4muscle.com | China | 10473 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6391 | 58 |
| TargetMol Chemicals Inc. | support@targetmol.com | United States | 38632 | 58 | |
| Wuhan Topule Biopharmaceutical Co., Ltd | +8618327326525 | masar@topule.com | China | 8467 | 58 |
| LEAPCHEM CO., LTD. | +86-852-30606658 | market18@leapchem.com | China | 43340 | 58 |
View Lastest Price from PF-04929113 manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2024-11-19 | PF04929113
908115-27-5
|
US $33.00-76.00 / mg | 99.06% | 10g | TargetMol Chemicals Inc. |
-
- PF04929113
908115-27-5
- US $33.00-76.00 / mg
- 99.06%
- TargetMol Chemicals Inc.